Dataset Information


Imprecise Kidney Function Thresholds in Cancer Clinical Trials and the Potential for Harm.

ABSTRACT: Current guidance for evaluation of kidney function and drug dosing emphasize using measured or estimated glomerular filtration rate (GFR) rather than measured or estimated creatinine clearance or serum creatinine (Scr) alone. We assessed the definitions of kidney function thresholds for eligibility in cancer clinical trials. A random sample of active Phase I-III trials with cisplatin (n = 465) and studies in cancer with decreased kidney function (n = 74) were identified from clinicaltrials.gov. Among cisplatin trials, kidney function thresholds were defined by Scr alone or a composite of Scr or creatinine clearance in 46% (212/465) of studies. Only 2% (n = 11) used GFR. Among trials in participants with decreased kidney function, the proportion utilizing GFR (14%, 10/74) was modestly higher. Imprecise and logically inconsistent kidney function thresholds are in frequent use in clinical trials in cancer and may cause harm from either toxicity or impaired efficacy. We recommend the adoption and harmonization of recommended standards.


PROVIDER: S-EPMC6649787 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4727919 | BioStudies
2017-01-01 | S-EPMC5641185 | BioStudies
2020-01-01 | S-EPMC7210480 | BioStudies
2015-01-01 | S-EPMC4418565 | BioStudies
1000-01-01 | S-EPMC6251639 | BioStudies
2020-01-01 | S-EPMC7151673 | BioStudies
2020-01-01 | S-EPMC7173781 | BioStudies
2019-01-01 | S-EPMC6761270 | BioStudies
2016-01-01 | S-EPMC4848755 | BioStudies
1000-01-01 | S-EPMC3781789 | BioStudies